| Literature DB >> 35326102 |
Ajay Kumar1, Rahul Prasad Singh2, Indrajeet Kumar2, Priya Yadav2, Sandeep Kumar Singh3, Prashant Kumar Singh4, Rajan Kumar Gupta2, Shiv Mohan Singh2, Mahipal Singh Kesawat5, Ganesh Dattatraya Saratale6, Sang-Min Chung7, Manu Kumar7.
Abstract
The world has faced the challenges of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) for the last two years, first diagnosed at the end of 2019 in Wuhan and widely distributed worldwide. As a result, the WHO has proclaimed the illness brought on by this virus to be a global pandemic. To combat COVID-19, researcher communities continuously develop and implement rapid diagnoses, safe and effective vaccinations and other alternative therapeutic procedures. However, synthetic drug-related side effects and high costs have piqued scientists' interest in natural product-based therapies and medicines. In this regard, antiviral substances derived from natural resources and some medicines have seen a boom in popularity. For instance, algae are a rich source of compounds such as lectins and sulfated polysaccharides, which have potent antiviral and immunity-boosting properties. Moreover, Algae-derived compounds or metabolites can be used as antibodies and vaccine raw materials against COVID-19. Furthermore, some algal species can boost immunity, reduce viral activity in humans and be recommended for usage as a COVID-19 preventative measure. However, this field of study is still in its early stages of development. Therefore, this review addresses critical characteristics of algal metabolites, their antioxidant potential and therapeutic potential in COVID-19.Entities:
Keywords: COVID-19; SARS-CoV-2; algae; antioxidants; antiviral; metabolites
Year: 2022 PMID: 35326102 PMCID: PMC8944855 DOI: 10.3390/antiox11030452
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
List of algae-derived metabolites and their bioactivity as antiviral compounds.
| Algal Species | Antiviral Metabolites | Mechanisms of Action | References |
|---|---|---|---|
| Alginate | Inhibition of inverse transcriptase in the RNA virus | [ | |
|
| Carrageenan | Inhibition of binding or internalization of viruses into host cells | [ |
|
| Dieckol; 8,8-bieckol | Protease inhibitor | [ |
| Exopolysaccharides | Internalization or virus binding on host cells is inhibited. | [ | |
| Fucoidan | Inhibition of adhesion and blocking of reverse transcriptase | [ | |
| Griffithsin | Griffithsin interacts with oligosaccharides components of spike glycoproteins of the various viruses. | [ | |
| Galactan | Blocking of virus adhesion and replication into host cells | [ |
Figure 1Bioactive metabolites extracted from algae and their possible approach to treating or preventing COVID-19.
Algae-derived antiviral pharmacologically active compounds and their targeted viruses.
| Marine Algal Source | Lectin Designated | Active against Viruses | References |
|---|---|---|---|
| GRFT | SARS-CoV, HCV, HIV | [ | |
|
| AML, HML, BSL, Sfl, MEL | HIV and influenza | [ |
|
| Cyanovirin | HIV | [ |
|
| Microvirin | HIV-1 | [ |
|
| MVL | HIV-1 | [ |
|
| ESA-2 | Influenza | [ |
|
| HRL40 | Influenza | [ |
|
| KAA-2 | Influenza | [ |
|
| Scytovirin | HCV, HIV, Ebola | [ |
Figure 2Molecular mechanism of seaweed polysaccharides (SPs) used as a potential biotherapeutic agent against SARS-CoV-2. The figure was modified from [45].
Antioxidant activity of secondary metabolites synthesized from macroalgae.
| Compound | Isolation Source | Assay/Activity | References |
|---|---|---|---|
| methyl-21-yl-[5′,6′-dihydro-5′-yl-{54-(4-hydroxybenzoyl)-oxy-(52-methylbutyl)}-3′-methyl-2H-pyran]-21-methyl butanoate (1), 11-[(3′,6′-dihydro-4′-methyl-2′-oxo-2H-pyran-3′-yl)methyl]-10-methylhexyl benzoate (2) and [6-ethyl-3,4-dimethyl-(tetrahydro-2′, 2′, 6′-trimethyl-2H-pyran-3′-yl)-2,5-cycloheptadiene]-1-propanoate (3) |
| DPPH radical scavenging activity with IC50 range from 0.54 to 1.1 mg mL−1 | [ |
| Fucoidan |
| DPPH radical scavenging activity | [ |
| methyl |
| DPPH radical scavenging activity: IC50 = 27.9 µM | [ |
| Sargachromanols |
| DPPH scavenging activity | [ |
| Odonthalol and Odonthadione |
| DPPH radical scavenging activity: IC50 = 24.7 ± 0.0 µM | [ |
| Pheophorbide A |
| The DPPH and hydroxyl radical scavenging capacities of the chloroform fraction were compared, butylated hydroxyanisole (BHA) and α-tocopherol, at concentrations ranging from 0.25 to 1.0 mg/mL. | [ |
| 4′-chloro-2-hydroxyaurone and 4−chloroaurone |
| O2− scavenging activity: IC50 = 22.2 µM | [ |
| Fucoidan |
| Scavenging of DPPH radicals: 9.01 ± 1.93 µg/mL | [ |
| 7-epi-silphiperfolan-6β-ol and silphiperfolan-7β-ol |
| Scavenging of DPPH radicals; 27.5 and 30.3% at 500 µg mL−1, respectively | [ |
| Cystoazorones A and B and cystoazorol A |
| Scavenging of DPPH radicals: 29% at 1.06 mM | [ |
| 3-(2,3-dibromo-4,5-dihydroxybenzyl)pyrrolidine-2,5-dione; methyl 4-(2,3-dibromo-4,5-dihydroxybenzylamino)-4-oxobutanoat;4-(2,3-dibromo-4,5-dihydroxybenzylamino)-4-oxobutanoic acid; 3-bromo-5-hydroxy-4-methoxybenzamide; and 2-(3-bromo-5-hydroxy-4-methoxyphenyl)acetamide |
| These compounds showed potent scavenging activity against DPPH radicals, with IC50 values ranging from 5.22 to 23.60 μM. | [ |
Figure 3An overview of the diversity of physiologically active antioxidants produced in algae and their possible therapeutic and biological potential.